Valuation
- Market cap
- 58,630,000
- Revenue TTM
- $43,770,000
- Net income TTM
- $-35,040,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -80.05%
- Debt to equity
- 0.00
Trading
- Volume
- 7,400
- Avg volume
- 12,490
- Day's range
- $8.89 – $9.07
- Shares out
- 6,580,000
- Stochastic %K
- 28%
- Beta
- -0.15
- Analysts
- Strong Sell
- Price target
- $20.00
Company profile
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart,...
Show more
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 524 2466
- Website
- https://xiliotx.com
- Address
- 828 Winter Street, Suite 300, Waltham, United States
Latest news
No headlines yet.
